Search
Copyright © 2025 ALM Global, LLC. All Rights Reserved.
Wegovy semaglutide injection pens. Credit: K KStock/Adobe StockThe new-generation weight-loss drugs work very well at preventing obesity, diabetes and death, but they are still much too expensive to be a good financial value for employer plans or other payers, researchers report in a new paper published by JAMA Health Forum.
Semaglutide, the GLP-1 agonist drug that powers Wegovy, could cost less than $100,000 per qualify-adjusted life year added once its price falls to $1,522 per year, from an average of about $8,412 per year today, the researchers estimate.
NOT FOR REPRINT
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Guide
Sponsored by Nonstop Administration and Insurance Services, Inc.
Everything You Need to Know About Medical Expense Reimbursement Plans (MERPs)
You can bet that many of your employer clients will be considering alternative funding models as they shop around for health plans this year. Download this short guide to learn about the difference between MERPs and HRAs, why they matter and how you can provide your clients with lower costs, more flexibility and greater satisfaction.
Guide
Sponsored by Nonstop Administration and Insurance Services, Inc.
Got a New Prospect? Change Your Next Conversation
Prioritizing health equity can transform your sales strategy and secure long-term business success. This guide helps you lead thoughtful conversations by aligning with employers' values.
Guide
Sponsored by Nonstop Administration and Insurance Services, Inc.
Broker Guide: Overcome Your Clients' Top 4 Cost Barriers
Discover innovative solutions to help your clients overcome cost barriers in health insurance.
Copyright © 2025 ALM Global, LLC. All Rights Reserved.
Sign In
Sign In
